HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Additive efficacy of CTLA4Ig and OX40Ig secreted by genetically modified grafts.

AbstractBACKGROUND:
The use of systemic immunosuppressive drugs have been paramount in the success in transplantation, but there are serious deleterious effects. Genetic modification of grafts to secrete immunomodulators locally may be a way to reduce the need for systemic immunosuppression.
METHODS AND RESULTS:
An insulinoma cell line, NIT, having the nonobese diabetic (NOD) genotype but also expressing the SV40 large T Ag, was transfected with CTLA4Ig or OX40Ig in an attempt to block signals in the costimulatory/adhesion pathways. The extracellular domains of these molecules have been fused to the Fc of IgG2c derived from the NOD mouse strain. This resulted in secreted and dimerized proteins. SV40 T Ag is potent at inducing graft rejection. Test and control transfectants were transplanted subcutaneously into young NOD mice to determine whether secretion of CTLA4Ig and OX40Ig would promote survival of the insulinoma graft. In immunodeficient mice, cell growth was similar for all transfectants. However, in immunocompetent NOD mice, the survival/growth of test grafts was significantly better than that of controls. By combining test transfectants, we found that graft survival was enhanced in an additive and significant fashion. In vitro, there was a significant reduction in immune responses-compared with control-when purified fusion proteins were added to mixed leukocyte reaction cultures.
CONCLUSIONS:
We conclude that blockade of individual costimulatory/adhesion signals by graft manipulation can contribute to transplantation success and that blockade of combinations of signals in these pathways enhances this success. Successful immunomodulation by the graft itself can be achieved.
AuthorsJ L Brady, A M Lew
JournalTransplantation (Transplantation) Vol. 69 Issue 5 Pg. 724-30 (Mar 15 2000) ISSN: 0041-1337 [Print] United States
PMID10755517 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.)
Chemical References
  • Antigens, CD
  • Antigens, Differentiation
  • CTLA-4 Antigen
  • Ctla4 protein, mouse
  • IgG2c receptor
  • Immunoconjugates
  • Immunoglobulin Fc Fragments
  • Insulin
  • OX40Ig
  • Receptors, Cell Surface
  • Receptors, IgG
  • Recombinant Fusion Proteins
  • Abatacept
Topics
  • Abatacept
  • Animals
  • Antigens, CD
  • Antigens, Differentiation (genetics, metabolism, therapeutic use)
  • CTLA-4 Antigen
  • Cell Division (drug effects)
  • Genetic Techniques
  • Immunocompetence
  • Immunoconjugates
  • Immunoglobulin Fc Fragments (genetics)
  • Insulin (biosynthesis)
  • Islets of Langerhans (drug effects, metabolism, pathology)
  • Islets of Langerhans Transplantation
  • Lymphocyte Culture Test, Mixed
  • Mice
  • Mice, Inbred CBA
  • Mice, Inbred NOD (physiology)
  • Mice, SCID
  • Receptors, Cell Surface (metabolism)
  • Receptors, IgG (genetics)
  • Recombinant Fusion Proteins (metabolism, physiology)
  • Transfection
  • Tumor Cells, Cultured (drug effects, metabolism, pathology, transplantation)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: